Coagulation Testing (PT/aPTT) in Rodenticide Toxicosis

Introduction

Anticoagulant rodenticide toxicosis represents a common and potentially fatal intoxication in companion animals, particularly dogs and cats, as well as in wildlife and avian species [1, 2]. The primary diagnostic tools for confirming and monitoring this condition are the prothrombin time (PT) and activated partial thromboplastin time (aPTT) assays [3, 4]. These coagulation tests measure the functional integrity of the extrinsic and intrinsic coagulation pathways, respectively, and are exquisitely sensitive to the depletion of vitamin K-dependent clotting factors (factors II, VII, IX, and X) caused by anticoagulant rodenticides [4, 5]. This article provides a detailed, publication-grade reference on the application, interpretation, and limitations of PT and aPTT testing in the context of rodenticide toxicosis.

Pathophysiology of Anticoagulant Rodenticide Toxicosis

Anticoagulant rodenticides, including first-generation compounds (e.g., warfarin, diphacinone) and second-generation compounds (e.g., brodifacoum, bromadiolone), act as vitamin K antagonists [3, 4]. These agents inhibit the enzyme vitamin K epoxide reductase, which is essential for the recycling of vitamin K from its epoxide form to its reduced, active form [4]. Reduced vitamin K is a required cofactor for the post-translational gamma-carboxylation of glutamic acid residues on the N-terminal domains of coagulation factors II (prothrombin), VII, IX, and X [4, 5]. Without this carboxylation, these factors are synthesized in the liver but are secreted as non-functional, decarboxylated proteins known as PIVKA (proteins induced by vitamin K absence or antagonism) [5]. The accumulation of PIVKA leads to a progressive coagulopathy that is detectable through prolongation of both PT and aPTT [3, 4].

Second-generation anticoagulant rodenticides (SGARs), such as brodifacoum and bromadiolone, have a significantly higher potency and longer half-life in the body compared to first-generation compounds [2, 3]. This is due to their greater lipophilicity and stronger binding affinity to vitamin K epoxide reductase, leading to a prolonged duration of coagulopathy that may persist for weeks after a single exposure [2, 3]. The clinical onset of bleeding is typically delayed by 24 to 72 hours post-ingestion, as the body must first deplete its existing stores of functional vitamin K-dependent factors [4, 6]. In a retrospective analysis of 88 human poisoning cases, the median latency period was 4 days (range 1 to 30 days) [6]. Similar temporal dynamics are observed in veterinary patients, although the exact latency can vary based on the dose, the specific rodenticide, and the species affected [1, 2].

The PT and aPTT Assays: Principles and Mechanisms

The PT assay evaluates the extrinsic and common coagulation pathways [5]. It measures the time (in seconds) for plasma to clot after the addition of tissue factor (thromboplastin) and calcium ions [5]. The PT is particularly sensitive to deficiencies of factor VII, which has the shortest half-life (approximately 4 to 6 hours in dogs) among the vitamin K-dependent factors [3, 4]. Consequently, PT prolongation is often the earliest detectable coagulation abnormality in anticoagulant rodenticide toxicosis [3, 4].

The aPTT assay evaluates the intrinsic and common coagulation pathways [5]. It measures the time for plasma to clot after activation of the contact activation pathway (factors XII, XI, prekallikrein, and high-molecular-weight kininogen) using a surface activator (e.g., kaolin, silica, or ellagic acid) followed by the addition of phospholipid and calcium [5]. The aPTT is sensitive to deficiencies of factors VIII, IX, XI, and XII, as well as the common pathway factors (X, V, II, and fibrinogen) [5]. In rodenticide toxicosis, aPTT prolongation occurs as the levels of factors IX and X decline, though it typically lags behind PT prolongation due to the longer half-lives of these factors [3, 4].

The combined use of PT and aPTT provides a comprehensive assessment of the coagulation cascade [5]. In the context of anticoagulant rodenticide exposure, the classic pattern is a prolongation of both PT and aPTT, with PT often being more severely and earlier affected [3, 4]. Isolated prolongation of PT alone can be seen in early or mild toxicosis, while prolongation of both tests indicates more advanced depletion of the vitamin K-dependent factors [3, 4]. A normal PT and aPTT effectively rules out significant anticoagulant rodenticide-induced coagulopathy, provided the tests are performed at an appropriate time after exposure [3, 4].

Clinical Indications for Coagulation Testing

Coagulation testing (PT/aPTT) is indicated in any patient presenting with unexplained hemorrhage, particularly if the bleeding is multifocal or involves body cavities, the respiratory tract, or the central nervous system [1, 7, 8]. Common clinical signs of anticoagulant rodenticide toxicosis include hematuria, epistaxis, hematemesis, melena, hemoptysis, subcutaneous hematomas, hemothorax, hemoperitoneum, and pulmonary hemorrhage [1, 7, 8, 6]. In a case series of five dogs, upper airway obstruction secondary to cervical or retropharyngeal hemorrhage was the presenting complaint [7]. Ocular signs such as hyphema and retinal hemorrhage are also reported [8]. In avian species, signs may include lethargy, pallor, and bleeding from the nares or oral cavity [9].

Coagulation testing should also be performed in any patient with a known or suspected history of rodenticide ingestion, even in the absence of clinical signs, to establish a baseline and guide prophylactic therapy [2, 3]. The test is also indicated for monitoring response to vitamin K1 therapy and for determining the duration of treatment required [3, 4].

Interpretation of PT and aPTT Results

Reference intervals for PT and aPTT vary by species, laboratory, and the specific reagents and analyzers used [5]. In general, a PT that is prolonged beyond the upper limit of the reference interval, or an aPTT that is similarly prolonged, is considered abnormal [5]. In cases of rodenticide toxicosis, the magnitude of prolongation can be dramatic. In a retrospective analysis of 88 human cases, the mean aPTT was 110 seconds (range 3.71 to 212 seconds) and the mean PT was 100 seconds (range 11.6 to 300 seconds), with a mean international normalized ratio (INR) of 9 (range 0.98 to 38.2) [6]. Similar magnitudes of prolongation are reported in veterinary cases [1, 3].

The following table summarizes the typical coagulation profile patterns in different stages of anticoagulant rodenticide toxicosis.

It is critical to note that a normal PT and aPTT do not rule out recent exposure if testing is performed before the depletion of existing factor stores [3, 4]. In such cases, repeat testing 24 to 48 hours later is recommended [3, 4]. Conversely, a prolonged PT and aPTT in a patient with a history of exposure is highly supportive of anticoagulant rodenticide toxicosis, though other causes of acquired coagulopathy (e.g., liver failure, disseminated intravascular coagulation, or vitamin K deficiency from malabsorption) should be considered in the differential diagnosis [5].

Diagnostic Workflow and Decision Tree

The following Mermaid diagram illustrates a recommended diagnostic workflow for a patient with suspected anticoagulant rodenticide toxicosis.

flowchart TD
    A[Patient presents with hemorrhage or known/suspected rodenticide exposure], > B{Perform PT and aPTT}
    B, > C{PT and aPTT within reference intervals?}
    C, >|Yes| D[Low suspicion of active coagulopathy. Consider repeat testing in 24-48 hours if high index of suspicion.]
    C, >|No| E{Is PT prolonged alone?}
    E, >|Yes| F[Early or mild toxicosis. Initiate vitamin K1 therapy. Monitor PT daily.]
    E, >|No| G{Are both PT and aPTT prolonged?}
    G, >|Yes| H[Moderate to severe toxicosis. Initiate aggressive vitamin K1 therapy. Consider fresh frozen plasma if life-threatening hemorrhage.]
    H, > I[Monitor PT and aPTT every 24-48 hours during therapy.]
    I, > J{Are values normalizing?}
    J, >|Yes| K[Continue vitamin K1 for 3-4 weeks for SGARs. Recheck PT 48-72 hours after cessation.]
    J, >|No| L[Re-evaluate dose and duration of vitamin K1. Consider other causes of coagulopathy.]
    K, > M{PT remains normal after cessation?}
    M, >|Yes| N[Successful treatment. Discontinue monitoring.]
    M, >|No| O[Relapse. Restart vitamin K1 therapy and extend treatment duration.]

Sample Collection and Handling

Accurate PT and aPTT results depend on meticulous sample collection and handling [5]. Blood should be collected via atraumatic venipuncture into a plastic or siliconized glass tube containing 3.2% (or 3.8%) sodium citrate at a ratio of 9 parts blood to 1 part anticoagulant [5]. Underfilling or overfilling the tube will alter the citrate-to-blood ratio and produce erroneous results [5]. The sample should be gently inverted to mix, then centrifuged to obtain platelet-poor plasma (typically at 1500 to 2000 g for 15 minutes) [5]. Plasma should be tested promptly or stored at 2 to 8 degrees Celsius for up to 4 hours, or frozen at -20 degrees Celsius for longer storage [5]. Hemolyzed, lipemic, or icteric samples may interfere with optical clot detection methods and should be avoided if possible [5].

Differential Diagnoses and Confirmatory Testing

While a prolonged PT and aPTT in a patient with a history of rodenticide exposure is highly suggestive, other causes of acquired coagulopathy must be considered [5]. These include severe liver disease (due to impaired factor synthesis), disseminated intravascular coagulation (DIC) (due to consumption of coagulation factors and platelets), and vitamin K deficiency secondary to biliary obstruction or severe malabsorption [5]. Inherited coagulation factor deficiencies (e.g., hemophilia A or B) are less common but can present with similar laboratory abnormalities [10]. In one reported case, a patient with combined inherited factor VII and factor X deficiency was initially misdiagnosed as having diphacinone rodenticide toxicosis, highlighting the importance of a thorough history and confirmatory testing [10].

Confirmatory testing for rodenticide exposure can be performed through the detection of the specific rodenticide compound in serum, plasma, or liver tissue using high-performance liquid chromatography (HPLC) or mass spectrometry [2, 6]. These methods are not routinely available in all clinical settings but are valuable for forensic or epidemiological purposes [2, 6]. In the absence of such testing, a positive response to vitamin K1 therapy (i.e., normalization of PT and aPTT within 24 to 48 hours) provides strong supportive evidence for anticoagulant rodenticide toxicosis [3, 4].

Species-Specific Considerations

While the fundamental pathophysiology of anticoagulant rodenticide toxicosis is similar across mammalian species, there are important species-specific differences in sensitivity and metabolism [2, 9]. Dogs are highly sensitive, and cases of brodifacoum toxicosis in whelping dogs have been reported, with the potential for transplacental or lactational transfer to puppies [2]. Cats are generally considered more resistant, but toxicosis does occur [5]. Avian species, such as the red-tailed hawk, are also susceptible, and diagnosis relies on the same principles of PT and aPTT prolongation [9]. In birds, the PT assay may require species-specific thromboplastin reagents for optimal accuracy [9].

Therapeutic Monitoring

The cornerstone of therapy for anticoagulant rodenticide toxicosis is the administration of vitamin K1 (phytonadione) [3, 4]. The initial dose is typically given subcutaneously or orally, with oral therapy being preferred for long-term management once the patient is stable [3, 4]. The duration of therapy depends on the type of rodenticide ingested. For first-generation compounds, 7 to 14 days of therapy may be sufficient, whereas for SGARs, 3 to 4 weeks or longer is often required due to the prolonged half-life of the toxin [2, 3]. Coagulation testing (PT and aPTT) is used to monitor the response to therapy [3, 4]. The PT should begin to normalize within 24 to 48 hours of initiating vitamin K1 therapy [3, 4]. If it does not, the dose may be inadequate, or the diagnosis may be incorrect [3, 4]. After the cessation of vitamin K1 therapy, the PT should be rechecked 48 to 72 hours later to ensure that a relapse has not occurred [3, 4]. A re-prolongation of PT at this point indicates persistent rodenticide body burden and the need for continued therapy [2, 3].

Frequently Asked Questions

What is the earliest coagulation test abnormality in anticoagulant rodenticide toxicosis?

The earliest coagulation test abnormality is a prolongation of the prothrombin time (PT), which reflects the rapid depletion of factor VII, the vitamin K-dependent factor with the shortest half-life [3, 4].

Can a normal PT and aPTT rule out rodenticide toxicosis?

A normal PT and aPTT can rule out active coagulopathy at the time of testing, but they cannot rule out recent exposure if testing occurs before the depletion of existing factor stores [3, 4]. Repeat testing 24 to 48 hours after exposure is recommended in such cases [3, 4].

How long after exposure should PT and aPTT be checked?

Coagulation testing should be performed as soon as possible after a known or suspected exposure, and repeated 24 to 48 hours later if initial results are normal [3, 4]. Clinical signs of bleeding typically develop 24 to 72 hours after ingestion [4, 6].

What is the typical pattern of PT and aPTT in severe toxicosis?

In severe toxicosis, both PT and aPTT are markedly prolonged, often to values several times the upper limit of the reference interval [1, 3, 6]. The PT is usually more prolonged than the aPTT in the early stages [3, 4].

How is the response to vitamin K1 therapy monitored?

The response to vitamin K1 therapy is monitored by serial PT and aPTT measurements, typically every 24 to 48 hours [3, 4]. Normalization of these values indicates adequate therapy [3, 4]. A recheck PT 48 to 72 hours after cessation of therapy is essential to detect relapse [2, 3].

What other conditions can cause prolonged PT and aPTT?

Other conditions that can cause prolongation of both PT and aPTT include severe liver disease, disseminated intravascular coagulation (DIC), and vitamin K deficiency from other causes such as biliary obstruction or malabsorption [5]. Inherited factor deficiencies, such as combined factor VII and X deficiency, can also mimic rodenticide toxicosis [10].

Is coagulation testing useful in avian species?

Yes, coagulation testing is useful in avian species, although species-specific thromboplastin reagents may be required for accurate PT measurement [9]. The same principles of PT and aPTT prolongation apply in birds with anticoagulant rodenticide toxicosis [9].

References

[1] Brei C, Stern L, Racette M. An atypical presentation of anticoagulant rodenticide toxicosis in a dog. Can Vet J. 2023. https://pubmed.ncbi.nlm.nih.gov/37915786/

[2] Fitzgerald SD, Martinez J, Buchweitz JP. An apparent case of brodifacoum toxicosis in a whelping dog. J Vet Diagn Invest. 2018. https://pubmed.ncbi.nlm.nih.gov/29145778/

[3] Woody BJ, Murphy MJ, Ray AC, et al. Coagulopathic effects and therapy of brodifacoum toxicosis in dogs. J Vet Intern Med. 1992. https://pubmed.ncbi.nlm.nih.gov/1548622/

[4] Mount ME, Feldman BF. Mechanism of diphacinone rodenticide toxicosis in the dog and its therapeutic implications. Am J Vet Res. 1983. https://pubmed.ncbi.nlm.nih.gov/6689111/

[5] Lanevschi-Pietersma A. Manual of Canine and Feline Haematology and Transfusion Medicine. 2003. https://www.semanticscholar.org/paper/9a3e4c8598acd7e42526ac412ddabcbcf16e35d9 *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[6] Yu Z, Zhang J, Yuan Y, et al. A retrospective analysis of 88 anticoagulant rodenticide poisoning cases: Characteristics and forensic implications. Forensic Sci Int. 2025. https://www.semanticscholar.org/paper/2414fde8033275c312c02bc105e41aaa50be9b40

[7] Lawson C, O'Brien M, McMichael M. Upper Airway Obstruction Secondary to Anticoagulant Rodenticide Toxicosis in Five Dogs. J Am Anim Hosp Assoc. 2017. https://pubmed.ncbi.nlm.nih.gov/28535134/

[8] Vallés N, Echalecu MS, Bernabe A, et al. Ultrasound features of an unusual intramural gastric haemorrhage secondary to rodenticide intoxication in a dog. Vet Rec Case Rep. 2023. https://www.semanticscholar.org/paper/120c1e41b8f712eaa098f58337b86bd50095126b

[9] Murray M, Tseng F. Diagnosis and treatment of secondary anticoagulant rodenticide toxicosis in a red-tailed hawk (Buteo jamaicensis). J Avian Med Surg. 2008. https://pubmed.ncbi.nlm.nih.gov/18543601/

[10] Li M, Jin Y, Wang M, et al. Diagnostic Error of a Patient with Combined Inherited Factor VII and Factor X Deficiency due to Accidental Ingestion of a Diphacinone Rodenticide. Clin Lab. 2016. https://www.semanticscholar.org/paper/228365656d3471f8e3e9ba4de88fe2c51f8adcad